Scroll to learn more
Referring Your Patient to a Clinical Trial
If you are interested in referring a patient to an AbbVie clinical trial, you may contact AbbVie at 844-663-3742 or [email protected] to get routed to the appropriate team that can assist you with locating and contacting an enrolling investigational site.
To explore resources that may help patients make informed decisions and feel supported throughout their healthcare journey, click here to visit our Patient Resource section.
Registry Reporting
We register and disclose the results of our clinical trials in publicly accessible clinical trial registries
Our approach to registration and result reporting
AbbVie shares study registrations and results globally by providing trial details here on AbbVie Clinical Trials, local country registries, and information made publicly available by the NIH in ClinicalTrials.gov and by the EMA in the Clinical Trial Information System (CTIS). Regardless of outcome, we disclose the results of our clinical trials in a publicly accessible clinical trial registry.
Historical results reporting
Prior to the availability of disclosing clinical trial results for pharmaceuticals on www.clinicaltrials.gov, AbbVie (prior sponsor, Abbott) disclosed certain clinical trial results on the Clinical Study Results Database created by the Pharmaceutical Research and Manufacturers of America (PhRMA). The database was phased out on December 20, 2011, but information previously posted is available here.
What did the PhRMA clinical study results database contain?
The database contained the results from all “hypothesis-testing” clinical studies (mainly Phase 3 and 4 studies) completed since October 1, 2002, for drug products approved in the United States. This included both published articles and unpublished study summaries. This information was presented in a standard format that included the sponsoring company’s name, the proprietary and generic names of the drug, a link or reference to the US Food and Drug Administration (FDA)-approved drug label, the studied indication(s), a bibliography of published studies together with a link (where available) to the printed articles and a summary of the results of clinical studies that have not been published. This summary presentation included information on the drug such as the design of the trial, the number of patients studied, the dose and mode of administration and a summary of conclusions and outcomes on the safety and efficacy of the drug.
Data Sharing
We recognize the benefits of sharing our clinical trial Data Sharing information with researchers
Our commitment to sharing data and information
Qualified researchers engaged in rigorous, independent scientific research can request access to our anonymized clinical trial data. Access will be provided following receipt of a research proposal and Statistical Analysis Plan (SAP), review of the proposal and SAP, and execution of a Data Use Agreement (DUA). All requests from qualified researchers for access to AbbVie clinical data and information will be managed by Vivli and AbbVie. To submit a request, visit Vivli.
How the process works
We provide researchers access to our data and information via a multi-step process.
Step 1
Submit a research proposal
Step 2
Review of research proposal
Access to data is determined based on the business feasibility to support the request and the scientific merit of the research proposal.
Proposals that have been received via Vivli will be reviewed by AbbVie for business feasibility. Proposals that are feasible to support are then reviewed for scientific merit by members of an Independent Review Panel (IRP), according to their charter. See Vivli for more information.
In determining whether a specific request for access to data and clinical trial information shall be granted, all relevant information shall be considered, including:
- data requested
- hypothesis to be tested and the rationale for the proposed research
- statistical analysis plan
- publication and posting plan
- qualifications and experience of requestor or intended researcher(s) and any potential conflicts of interest
- source of any research funding
Interactions between our company, the IRP, and requestors of access to data and information are intended to be collaborative in nature.
Researchers are responsible for gaining any other approvals that are required for the research (for example, from ethics committees, institutional review boards, relevant research institutions or funding bodies).
Step 3
Access to data
We strive to respond to the requestor within a reasonable period of time from submission of a completed research proposal. When the request is approved, Vivli will initiate a Data Use Agreement (DUA). Once the DUA is executed, the anonymized data will be uploaded on the Vivli platform for access by the requestor.
We encourage researchers to provide the DUA template to relevant legal staff at their institution after proposal submission so it can be signed quickly following approval of the research proposal.
How the data is provided
Access to data needed for research is provided on a password protected platform via Vivli. This platform allows researchers to conduct research on the site and to download their analyses. Access is provided at no cost for 12 months.
Researchers are invited to conduct their research in a private workspace. This workspace is not accessed by AbbVie or any other third party unless researchers provide permission. Controls are in place to prevent the download of the anonymized data sets shared by AbbVie, to protect research participants privacy and confidentiality and ensure the data is used for the agreed research purpose.
Statistical software that is provided
Commonly used statistical software is provided on the platform so researchers can conduct their analyses. More information about the available software is on Vivli.
Step 4
Disclosure of research results
After the researcher has completed the research per the approved study proposal and analysis plan, the researcher is expected to publicly share the results per the executed DUA.
Metrics
Metrics from research proposals received from January 1, 2014 through July 19, 2018 are found here. Metrics for research proposals received after July 19, 2018 are on Vivli.
Approved research proposals
Metrics from research proposals received from January 1, 2014 through July 19, 2018 are found here. Metrics for research proposals received after July 19, 2018 are on Vivli.
Publications
We share the results of our clinical trials in peer-reviewed journals and at professional scientific meetings
Our commitment to publication of results
We submit manuscripts for publication in peer reviewed scientific and medical journals, with publication in the journals subject to the peer review process at the discretion of the journal editors.
For all AbbVie-sponsored Phase 2-4 clinical trials (and all other interventional trials of medical significance) a manuscript will be submitted to peer reviewed scientific and medical journals for publication. This includes compounds or devices where development has been discontinued.
We also disclose clinical trial results by submitting abstracts and presenting posters and oral presentations at professional scientific meetings.
RETURN OF TREATMENT ASSIGNMENTS
Patients are at the heart of AbbVie’s research activities. We empower patient voices to be heard and help guide our decision-making processes to advance cutting-edge science.
AbbVie aligns its patient-centric initiatives with international guidelines and regulations. This alignment is highlighted with our Plain Language Summaries of Results and Return of Treatment Assignments (RTA).
To adhere to the European Medicines Agency’s International Council for Harmonisation (ICH) E6(R3) guideline, AbbVie developed an automated RTA process in early 2025.
Within approximately 3 months of study completion and unblinding, treatment assignment information is distributed to study sites by email. This information is shared for all study phases and areas of research focus.
Treatment assignment information aids study doctors and study participants in making informed decisions about their next treatment options. RTA exemplifies the creativity, resourcefulness, and technological advancements needed to best serve patients.
Interested In Joining Our Clinical Trial Site Network?
AbbVie partners with leading scientific and medical professionals around the world to conduct clinical trials. We value the significant contributions that our scientific and medical professional partners make to our scientific innovation. AbbVie is committed to establishing collaborative partnerships to continuously grow our clinical trial site network.
To become a clinical trial investigator / investigative site on an AbbVie trial, submit your interest here: investigatorinquiry.abbvie.net.